Exopharm Limited (ASX:EX1)

47.5¢

right-arrow Created with Sketch. 0.005 (1.06%)
MCAP $73.88M
Last trade 15.56pm 19/01/2022 20mins delayed

Latest Announcements

04/01/2022EX1Exopharm Limited
04/01/2022EX1Exopharm Limited
04/01/2022EX1Exopharm Limited
29/12/2021EX1Exopharm Limited
22/12/2021 Price SensitivePSEX1Exopharm Limited
25/11/2021EX1Exopharm Limited
16/11/2021EX1Exopharm Limited
27/10/2021 Price SensitivePSEX1Exopharm Limited

Company Overview

Exopharm Limited is an Australia-based clinical-stage biopharmaceutical company that operates in the healthcare sector. The Company is focused on developing and commercializing exosomes as therapeutic agents. The Company has three technologies that allows customization of exosomes, in which the LOAD technology improves loading of nucleic medicines into exosomes and the EVPS technology allows exosomes to be directed towards selected cell types. Its LEAP manufacturing technology provides access to exosomes for research and clinical uses. The Company is developing Engineered EVs (EEVs), are an emerging form of precision medicine with application in areas, such as neurology, cardiology and oncology. Its EEV projects under development are Fortrexo, Cognevo and PlexoDOX.

EX1 in the news

Exopharm Limited (EX1) announced the company has been granted a US patent…
Exopharm (EX1) says it’s a step closer towards being granted a US…
Regenerative medicine company Exopharm (EX1) has received firm commitments to raise $12…
Exopharm (EX1) shares have bounced back after the company received positive results…

Search Previous Announcements